AARS Protein Fragment Discovery for Therapeutic Applications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aminoacyl-tRNA synthetases (AARS) have primarily been studied for their role in protein translation, with their full-length sequences well-characterized, but their protein fragments have not been systematically analyzed for novel biological activities or therapeutic potential, despite exhibiting extracellular signaling and other non-canonical activities.
Innovation Solution
Identification and characterization of resected protein fragments of AARS, referred to as resectins or appendacrines, through methods like mass spectrometry, deep sequencing, and bioinformatics, which reveal their potential as biotherapeutic, diagnostic, and drug target agents for various diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If full-length AARS sequences are studied for their canonical aminoacylation function, then the understanding of protein translation is improved, but the discovery of novel biological activities in AARS fragments is neglected
Solution Approach 1:
The patent systematically segments full-length AARS proteins into multiple fragments through proteolytic digestion and alternative splicing analysis. This segmentation reveals that AARS fragments possess novel biological activities (such as extracellular signaling and angiogenesis modulation) distinct from the canonical aminoacylation function of full-length proteins, thereby recovering lost information about fragment-specific functions.
Solution Approach 2:
The patent extracts AARS fragments from their parental full-length sequences through proteolysis and identifies them as distinct entities with independent biological functions. This extraction process allows the fragments to be studied separately, revealing their novel activities in extracellular environments and their potential as therapeutic agents without the constraints of full-length protein context.
2Ease of manufacture
If AARS fragments are not systematically analyzed, then the canonical function of AARS is maintained, but the therapeutic potential of AARS fragments is lost
Solution Approach 1:
The patent performs preliminary systematic analysis of AARS fragments through mass spectrometry, deep sequencing, and bioinformatics before therapeutic development. This preliminary characterization identifies fragments with novel biological activities and validates their therapeutic potential, enabling easier subsequent development of fragment-based therapeutics without repeating exploratory research.
Solution Approach 2:
The patent changes the research parameter from studying full-length AARS proteins to systematically analyzing AARS fragments. This parameter change reveals fragments with improved therapeutic properties such as reduced immunogenicity, enhanced stability, and novel extracellular signaling functions, thereby recovering lost therapeutic relevance information.
3Loss of information
If AARS fragments are expressed and purified for activity testing, then novel non-synthetase activities are discovered, but the complexity of protein purification increases
Solution Approach 1:
The patent segments AARS proteins into smaller fragments that are inherently easier to purify and characterize. The systematic fragmentation approach, combined with affinity tags and optimized purification protocols, reduces the complexity of purification while enabling comprehensive discovery of novel non-synthetase activities in fragment pools.
Solution Approach 2:
The patent develops universal purification and characterization methods that can be applied to multiple AARS fragments simultaneously. By using common protocols for fragment expression, purification, and activity screening, the complexity of analyzing multiple fragments is reduced while maintaining comprehensive coverage of novel biological activities.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.